Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based first-line phase 3 study in unresectable or metastatic urothelial carcinoma
NL-OMON56458Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, gemcitabine, cisplatin and carboplatin in transitional cell carcinoma (TCC) and bladder cancer (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival in cisplatin-ineligible participants and Overall survival in PD-L1-positive participants. Started May 2017; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON56458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56458.